Table 2. Results of multivariate analysis for 236 pairs with T3-4N0-1 NPC.

Endpoints	Variable	HR (95%CI)	Pa
OS b	Treatment group, CCRT plus IC/AC vs. CCRT alone	0.964 (0.620-1.499)	0.869
	Overall stage, IV vs. III	2.682 (1.289-5.580)	0.008
DFFS c	Treatment group, CCRT plus IC/AC vs. CCRT alone	1.036 (0.626-1.714)	0.890
	Overall stage, IV vs. III	2.099 (1.139-3.868)	0.005
LRFFS d	Treatment group, CCRT plus IC/AC vs. CCRT alone	0.670 (0.338-1.327)	0.250

NPC = nasopharyngeal carcinoma; OS = overall survival; DFFS = distant failure-free survival; LRFFS = locoregional failure-free survival; HR = hazard ratio; CI = confidence interval; CCRT = concurrent chemoradiotherapy; IC = induction chemotherapy; AC = adjuvant chemotherapy.

^a Multivariate P-values were calculated using an adjusted Cox proportional-hazards model with backward elimination and the following parameters: age (≥ 49y vs. < 49y), gender (male vs. female), smoking (yes vs. no), drinking (yes vs. no), KPS (≥ 90 vs. ≤ 80), N category (N1 vs. N0), overall stage (IV vs. III), concurrent chemotherapy regimen (TP vs. PF) and treatment group (CCRT plus IC/AC vs. CCRT).

^b Forty patients in the CCRT and 40 patients in the CCRT plus IC/AC were dead (P = 1.000).

^c Thirty-one in the CCRT and 32 patients in the CCRT plus IC/AC experienced distant metastasis (P = 0.892).

^d Twenty in the CCRT and 15 patients in the CCRT plus IC/AC developed locoregional recurrence (P = 0.380).